Pfizer to Seek Litfulo Approval for Vitiligo After Two Positive Phase 3 Trials

Pfizer plans to ask regulators to approve its oral drug Litfulo for vitiligo, after two late-stage trials showed it helped restore skin pigment better than placebo.

Announced July 30, 2026, the company intends to submit global filings for Litfulo (ritlecitinib) as an oral systemic treatment for nonsegmental vitiligo (NSV) in adults. There is currently no approved oral therapy specifically for it.

What vitiligo is

NSV is a chronic autoimmune disease in which the immune system attacks the melanin-producing cells that give skin its colour, leaving white patches.

Those cells — melanocytes — sit in the base layer of the epidermis and transfer pigment to surrounding skin cells. When they are destroyed, the skin loses colour in that area entirely rather than partially.

The nonsegmental form typically appears symmetrically on both sides of the body and progresses unpredictably, with periods of stability and periods of rapid spread. The segmental form is localised to one area and behaves differently, which is why the distinction appears in the indication.

Why treatment is difficult

Restoring pigment requires two things: stopping the immune attack, and repopulating the area with melanocytes.

The second is the harder part and explains why response is slow. Melanocytes repopulate from reservoirs in hair follicles, migrating outward from them into depigmented skin — which is why repigmentation often appears as spots around hairs that gradually merge.

Areas with few hair follicles, such as the hands and around the lips, repigment poorly for that reason. It also explains why treatment takes months to show effect even when the immune attack is controlled promptly.

What the trials showed

The filing is backed by TRANQUILLO and TRANQUILLO 2. Both the 50 mg and 100 mg doses produced significant improvements over placebo on the co-primary endpoints.

After 52 weeks, more patients on Litfulo reached F-VASI75 — at least 75% improvement in facial pigmentation — and T-VASI50, at least 50% improvement across the whole body. TRANQUILLO enrolled patients aged 12 and up; TRANQUILLO 2 studied adults.

Why two endpoints with different thresholds

Measuring face and body separately, at 75% and 50% respectively, reflects both the disease and what matters to patients.

Facial vitiligo has disproportionate psychological impact because it is unconcealable, and the face responds better to treatment than most sites — it is well supplied with hair follicles and receives sun exposure that stimulates melanocyte activity. A demanding threshold there is achievable.

Whole-body response is slower and less complete, since it includes the areas that repigment poorly. Setting 50% acknowledges that near-complete body repigmentation is not a realistic bar within a year.

Requiring both prevents a misleading result: a drug clearing faces while doing nothing elsewhere would pass one endpoint and should not count as effective for the disease.

Building on an existing approval

Litfulo is not new: the FDA approved it in 2023 for severe alopecia areata, an autoimmune form of hair loss, in adults and adolescents 12 and older.

The two conditions share more than an autoimmune label. Both involve immune attack on a specific cell population — melanocytes in one, hair follicles in the other — driven substantially by the same signalling pathways, which is why a drug blocking those pathways would plausibly work in both.

Ritlecitinib inhibits JAK3 and a related kinase family, interrupting signals that immune cells use to coordinate the attack. Drugs in this class have shown activity across several autoimmune skin conditions for the same reason.

What an oral option would change

Existing treatment is largely topical — steroids or calcineurin inhibitors applied to affected areas — sometimes with phototherapy requiring repeated clinic visits.

Topical treatment is impractical for extensive disease: applying cream to large body areas twice daily for months is a substantial burden, and adherence falls accordingly. A systemic oral drug treats everywhere at once.

What to watch

Pfizer did not give a precise regulatory timeline and said additional results will be presented at a future medical meeting.

Why vitiligo was treated as cosmetic for so long

The absence of approved systemic therapy until recently reflects how the condition was classified rather than how it affects people.

Vitiligo causes no physical symptoms. It does not itch, hurt or shorten life, and skin function is otherwise normal apart from increased sunburn risk in depigmented areas. On that basis it was long categorised as cosmetic, which shaped both research investment and insurance coverage — treatment was frequently excluded as an aesthetic concern.

Studies of psychological impact have made that position harder to sustain. Rates of depression, anxiety and social avoidance among people with visible vitiligo are substantially elevated, and the effect is greater in those with darker skin, where the contrast is more pronounced, and in cultures where the appearance carries stigma or is confused with infectious disease.

Reclassifying it as a chronic autoimmune disease with psychological consequences rather than a cosmetic variant is what made systemic treatment a reasonable proposition — and what makes coverage of an oral drug a live question rather than a settled exclusion.

The full data will matter, particularly safety. JAK inhibitors carry class warnings regarding serious infections, blood clots and cardiovascular events, and the tolerance for those risks is lower in a condition that is disfiguring rather than dangerous. Approval decisions rest with regulators reviewing the complete data. Regulatory news, not medical advice.